Amobarbital


Generic Medicine Info
Administration
May be taken with or without food.
Contraindications
Dyspnoea or airway obstruction, porphyria, sleep apnoea, pre-existing CNS depression or coma. Severe hepatic impairment.
Special Precautions
Patient w/ CV disease, depression or suicidal ideation, history of drug addiction or acute alcoholism. Renal and mild to moderate hepatic impairment. Elderly and debilitated patients, childn. Pregnancy and lactation. Patient Counselling May impair mental or physical abilities requiring mental alertness (e.g. driving or operating machinery). Monitoring Parameters Monitor vital signs during and after admin.
Adverse Reactions
Bradycardia, syncope, hypotension; apnoea, atelectasis (post-op), hypoventilation; agitation, anxiety, ataxia, confusion, CNS depression, dizziness, fever, hallucinations, headache, insomnia, nightmares, nervousness, psychiatric disturbances, somnolence, abnormal thinking; hyperkinesias; nausea, vomiting, constipation; liver damage; megaloblastic anaemia (following chronic phenobarbital use); angioedema, rash; inj site reaction.
Potentially Fatal: Erythema multiforme and exfoliative dermatitis.
Drug Interactions
May reduce plasma levels of oral anticoagulants (e.g. warfarin, dicoumarol, acenocoumarol, phenprocoumon), corticosteroids, griseofulvin, doxycycline, Na valproate and valproic acid. Constant monitoring of blood levels when concomitantly used w/ phenytoin. May increase CNS depressant effect w/ antihistamines, sedative/hypnotics, tranquilisers. May prolong the effect w/ MAOIs. May reduce the effect of estradiol, progesterone, estrone and other steroidal hormones.
ATC Classification
N05CA02 - amobarbital ; Belongs to the class of barbiturates. Used as hypnotics and sedatives.
Disclaimer: This information is independently developed by CIMS based on amobarbital from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in